Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Core Insights - The new clinical data confirms the potential of nebokitug (CM-101) as a first-in-class treatment for primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases [2][8] - Comprehensive proteomic analyses indicate that treatment with nebokitug resulted in significant and dose-dependent improvements in various biomarkers related to fibro-inflammatory disease pathways [2][3] - The pharmacokinetic and pharmacodynamic data from the Phase 2 SPRING trial demonstrate effective and dose-dependent antibody-target engagement [4][8] Group 1: Clinical Data and Findings - Nebokitug-treated patients exhibited significant and dose-dependent changes in multiple proteins related to fibrosis, immune cell recruitment, and inflammation [2][3] - The treatment was linked to downregulation of disease-related proteins and pathways involved with leukocyte migration, cytokine activity, chemokine activity, and collagen binding [3] - The analysis provided new insights into PSC disease-related pathways and additional biological evidence of the clinical activity of nebokitug [2] Group 2: Pharmacokinetics and Pharmacodynamics - PK analyses indicated dose-proportional increases in the concentration of nebokitug, with steady-state levels achieved after the fourth dose [4] - Increased levels of nebokitug corresponded with increased levels of its CCL24 target, reflecting effective antibody-target engagement [4] - Linear regression analyses found trends between increasing patient exposure to nebokitug and decreasing levels of relevant PSC disease biomarkers, including liver enzyme and transient elastography scores [4] Group 3: Company Overview and Future Plans - Chemomab Therapeutics is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [8] - The company has reported positive results from four clinical trials of nebokitug and is preparing for a potential Phase 3 trial based on positive data from the Phase 2 SPRING trial [8] - Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC [8]